Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.
via Wikipedia infobox
{{Infobox drug | image = Palbociclib skeletal formula.svg | image_class = skin-invert-image | alt = | caption = | image2 = Palbociclib ball-and-stick model from xtal 2023.png | image_class2 = bg-transparent
| tradename = Ibrance, others | Drugs.com = | MedlinePlus = a615013 | DailyMedID = Palbociclib | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth | ATC_prefix = L01 | ATC_suffix = EF01
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).